MARKET

IDYA

IDYA

Ideaya Bioscienc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.40
+0.86
+4.90%
Closed 19:05 01/22 EST
OPEN
17.54
PREV CLOSE
17.54
HIGH
18.80
LOW
17.40
VOLUME
193.01K
TURNOVER
--
52 WEEK HIGH
20.75
52 WEEK LOW
2.950
MARKET CAP
534.88M
P/E (TTM)
-9.7396
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-Rtw Investments LP Reports 7.21% Passive Stake In Ideaya Biosciences
reuters.com · 2d ago
--Analyst Actions: Wedbush Lifts Price Target for IDEAYA Biosciences to $25 From $21, Maintains Outperform Rating
MT Newswires · 3d ago
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 4d ago
BRIEF-IDEAYA Biosciences May Offer, Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $90 Million From Time To Time
reuters.com · 4d ago
Ideaya Biosciences sells ~3M shares for $50M gross proceeds
Ideaya Biosciences ([[IDYA]] +0.8%) sold ~3.1M shares for aggregate gross proceeds of ~50M at a weighted average price of $16.08 per share.Jefferies, the sales agent, receives 3% commission of the
Seekingalpha · 5d ago
IDEAYA Biosciences Announces Student Professional Development Partnership With Spelman College
ATLANTA, Ga. and SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 /PRNewswire/ -- Spelman College and IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announce partnership for professional development of
Benzinga · 6d ago
Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry
ATLANTA, Ga. and SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 /PRNewswire via COMTEX/ -- ATLANTA, Ga. and SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021...
PR Newswire - PRF · 6d ago
Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry
, Ga. and , /PRNewswire/ -- and IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announce partnership for professional development of the next generation of female African American leaders in the biotechnology industry through the and IDEAYA Biosciences Health S...
PR Newswire - PRF · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IDYA. Analyze the recent business situations of Ideaya Bioscienc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IDYA stock price target is 25.00 with a high estimate of 30.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 90
Institutional Holdings: 18.12M
% Owned: 62.35%
Shares Outstanding: 29.07M
TypeInstitutionsShares
Increased
26
983.54K
New
28
186.16K
Decreased
14
763.29K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/Independent Director
Tim Shannon
Chairman/Independent Director
Timothy Shannon
President/Chief Executive Officer/Director
Yujiro Hata
Chief Financial Officer
Paul Stone
Senior Vice President/Chief Scientific Officer
Michael Dillon
Senior Vice President
Mark Lackner
Vice President - Finance
Andres Briseno
Vice President/General Counsel/Secretary
Jason Throne
Vice President/Director of Human Resources
Julie Patel
Vice President
Paul Barsanti
Vice President
Mick O'Quigley
Independent Director
Garret Hampton
Independent Director
Scott Morrison
Independent Director
Terry Rosen
Independent Director
Thilo Schroeder
Independent Director
Jeffrey Stein
Independent Director
Wendy Yarno
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IDYA
IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company. The Company focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company’s product candidate is IDE196, a protein kinase C (PKC), inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes multiple synthetic lethality programs, including against methionine adenosyltransferase 2a (MAT2A) in tumor cells having methylthioadenosine phosphorylase (MTAP) gene deletion; Pol-theta, in tumors with genetic mutations in homologous recombination deficiency (HRD), including breast carcinoma (BRCA ) mutations; poly adenosine diphosphate-ribose glycohydrolase (PARG), in tumors with genetic mutations in BRCA or base excision repair, and WRN, in high microsatellite instability tumors (MSI) tumors.
More

Webull offers kinds of Ideaya Biosciences Inc stock information, including NASDAQ:IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.